Physician profile
Sergey Zhitnikov
NPI 1083640478
$1,688.40
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $31.65 · 2021: $81.72 · 2022: $406 · 2023: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $644.90 | 2019-2023 | Da Vinci Surgical System |
| Davol INC. | $251.34 | 2019-2023 | Phasix Mesh |
| Becton, Dickinson and Company | $177.18 | 2019 | |
| Baxter Healthcare | $141.68 | 2022 | |
| Allergan, INC. | $114.32 | 2019 | |
| Novo Nordisk INC | $96.47 | 2019-2023 | |
| W. L. Gore & Associates, INC. | $81.72 | 2021 | |
| Heron Therapeutics, INC. | $61.14 | 2023 | Aponvie |
| Covidien LP | $28.21 | 2019 | |
| Bard Access Systems, INC. | $24.06 | 2019 | |
| Ethicon US, LLC | $21.69 | 2023 | Enseal, Echelon; Endopath |
| Takeda Pharmaceuticals U.S.A., INC. | $19.98 | 2020 | |
| Tei Biosciences INC | $14.27 | 2019 | |
| Intra-Sana Laboratories | $11.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergey Zhitnikov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.